Clinical Trials Logo

Clinical Trial Summary

Cystic Fibrosis (CF) affects more than one body system, mainly respiratory and digestive.The quality of life of individuals with CF is adversely affected by the increasing treatment burden in addition to multi-system involvement. The International Classification of Functioning, Disability and Health (ICF) describes human functioning and states of disability and provides a framework for organizing this information. ICF Core Sets are created by selecting the appropriate categories for the current disease from the ICF classification. ICF Core Sets are smaller than ICF, allowing practical evaluation based on ICF in clinical use. It evaluates the current situation of the patient quickly and practically, and improves interdisciplinary cooperation. Our study, it was aimed to develop a core set that quickly and practically evaluates the current state of the patient with CF in Turkey, based on ICF, and increases coordination within the interdisciplinary team. In our study, the established, very comprehensive, scientific and evidence-based guide that should be followed while creating the ICF core set will be followed. The guide consists of 4 stages: The first stage is the literature review which allows us to see the disease from the perspective of the researcher by scanning the studies on CF in the last 10 years. The second stage is the patient interview, which includes interviewing these individuals, and allows us to see the disease from the perspective of individuals diagnosed with CF. The third phase is the expert questionnaire, which we will look at from the perspective of health professionals who are knowledgeable about treating individuals with CF. The fourth stage is the consensus stage, where the final core set is decided, which includes team discussion. With the final core set developed as a result of these stages, a core set that will quickly and practically evaluate the current situation of the patient with CF in Turkey based on ICF and increase coordination within the interdisciplinary team will be ensured. Hypothesis(s) and purpose(s) on which this thesis proposal is based: H1: The ICF Core Set will be instrumental in understanding CF-specific health, disability, and function. H2: It will be a step in the development of a standard tool for the assessment of adults with CF. In our study, we propose to examine CF from the perspective of the researcher as a result of the literature review, from the perspective of the patient as a result of the qualitative research, from the perspective of the health professional as a result of the expert survey, to create a core set specific to these patients, and thus to see the different characteristics of individuals with CF in terms of function, activity, participation, and environmental factors.


Clinical Trial Description

Cystic Fibrosis (CF) is a chronic, progressive, and autosomal recessive disease that shortens life expectancy caused by mutations in the Cystic Fibrosis Transmembrane Regulator (CFTR ) gene. It affects more than one body system, mainly the respiratory and digestive. The quality of life of individuals with CF is adversely affected by the increasing treatment burden in addition to multi-system involvement. Disorders in CF affect the structures and functions of various systems, especially the respiratory and digestive systems. This influence causes a decrease in the activity and participation of individuals with CF. Factors such as age, gender, and coping strategies of individuals may affect the severity of these symptoms in individuals with CF. Scientific advances in biology in CF have provided therapeutic diversity, thereby improving patient care and prolonging survival. Pancreatic enzyme supplementation, airway cleansing, long-term antimicrobial therapy for respiratory tract infection, and nutritional supplements are among the current treatments. CFTR modulators, which have been developed in recent years to improve CFTR protein function, have been reported to greatly benefit individuals with CF. It can be said that the life expectancy of individuals with CF is prolonged by developing-changing treatment strategies and multidisciplinary approaches. It has been reported in international records that approximately 150,000 patients worldwide have been diagnosed with CF. The incidence of the disease is estimated to be 1/3,000 live births in Northern Europe, 1/4.000-10,000 in Latin Americans, and 1/15,000-20,000 in African-Americans. There is limited number of studies on the incidence of CF in Turkey. In the study conducted by Gurson in 1973, the incidence of CF was determined as 1/3,000. According to the annual records of the Cystic Fibrosis Society of Turkey, there are 1930 CF patients followed in various centers in 2021 in Turkey. The International Classification of Functioning, Disability, and Health (ICF) describes human functioning and states of disability and provides a framework for organizing this information. The World Health Organization approved the ICF in 2001 to classify and describe patients' functions within the specific social and environmental context in which they live. ICF not only defines the health status of individuals but also allows health professionals to create a common language. The ICF includes five interrelated components: body functions (b), body structures (s), activity and participation (d), environmental factors (e), and personal factors. ICF, each of these components is hierarchically structured for one, followed by the second, third, and fourth levels. As you progress from the first to the fourth level, the descriptions of the categories become more detailed. Since it contains ICF 1495 categories, it is practically difficult to apply in clinical settings. Disease-specific assessment tools are required because diseases affect people in many ways. Therefore, there is a need to create disease-specific subsets of ICF categories that will make it easier to apply in the clinic. For this reason, the ICF Core Set is designed to be purposeful, and essential and can be used in daily clinical practice. ICF Core Sets are created by selecting the appropriate categories for the current disease from the ICF classification. ICF Core Sets are smaller than ICF, allowing practical evaluation based on ICF in clinical use. It evaluates the current situation of the patient quickly and practically, and improves interdisciplinary cooperation.Work is underway to develop the ICF Core Set, which is internationally recognized shortlist of the most relevant and essential ICF categories that can be used to assess and document the condition of patients living with a particular health condition. Core sets have been developed for various health conditions such as neurological, pediatric, cardiopulmonary, musculoskeletal, and cancer. Studies investigating Cystic Fibrosis from the ICF perspective are limited, but there are no studies within the scope of the core set. Our study, it was aimed to develop a core set that quickly and practically evaluates the current situation of the patient with CF in Turkey based on ICF and increases the coordination within the interdisciplinary team. In our practice, we will follow an established, very comprehensive, scientific and evidence-based guide published by the 'ICF Research Branch', which should be followed when creating the ICF-Core Set. The research consists of 4 steps. A 'literature review' that allows us to view primary care CF from the perspective of the investigator. In this step, studies on CF for the last 10 years will be searched from various databases (PUBMED, Scopus, Embase). Literature Review-Inclusion Criteria - Studies with individuals over the age of 18 with a diagnosis of Cystic Fibrosis - Studies published in the last 10 years - Studies in English - Randomized controlled, clinical control study, observational studies, cross-sectional studies, qualitative studies Literature Review - Exclusion Criteria -Psychometric and prevention studies, phase II clinical research studies, studies with laboratory parameters only, animal experiments, letters, comments and editorials Qualitative research that allows us to view second-line CF from the perspective of individuals diagnosed with CF. It is planned to reach adult individuals who are followed up with the diagnosis of CF in Hacettepe University Department of Chest Diseases and referred to Hacettepe University Faculty of Physical Therapy and Rehabilitation. Focus group discussions with a maximum of 7 people will be held. With the guidance of the moderator, 6 open-ended questions covering the components of the ICF will be asked. Qualitative Research- Inclusion Criteria - Individuals over the age of 18 with a diagnosis of CF - Volunteering to participate in research The 'expert survey' allows us to see tertiary CF through the eyes of healthcare professionals. At this step, 6 open-ended questions covering ICF components for individuals with CF will be asked via e-mail to healthcare professionals who treat individuals with CF or have experience in research in this field. We are planning to reach the physicians working in the field of CF in the Hacettepe University Chest Diseases Department and the people with whom these physicians are in the National Cystic Fibrosis Patient Registry and collaborate. We plan to reach physiotherapists who work with patients diagnosed with CF academically and clinically at Hacettepe University Faculty of Physical Therapy and Rehabilitation, and physiotherapists who have experience in this field in different centers. Other health professionals (dieticians, nurse) who are familiar with the problems related to CF will be reached with the cooperation of physicians and physiotherapists. Expert Questionnaire-Inclusion Criteria - Have at least three months of experience in treating and/or researching individuals with CF, with knowledge of CF-related problems - Volunteering to participate in research The fourth step is the 'consensus' that we will create the final Core Set as a result of the data we collect. A multidisciplinary team (Physician, Physiotherapist, Dietitian, Nurse) meeting will be held for the Short Core Set created in this step. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06128499
Study type Observational
Source Hacettepe University
Contact Nisa AKYAZI, B.Sc
Phone +90 539 506 63 61
Email nisaakyazi@hotmail.com
Status Not yet recruiting
Phase
Start date March 10, 2024
Completion date March 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A